Alimera Sciences (NASDAQ:ALIM)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued to investors on Monday. They presently have a $5.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 309.84% from the company’s previous close.

ALIM has been the subject of a number of other research reports. Zacks Investment Research upgraded Alimera Sciences from a “sell” rating to a “hold” rating in a research note on Monday, January 8th. Cowen reiterated a “buy” rating on shares of Alimera Sciences in a research note on Thursday, November 2nd. Finally, ValuEngine cut Alimera Sciences from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $3.38.

Shares of Alimera Sciences (NASDAQ:ALIM) opened at $1.22 on Monday. The company has a quick ratio of 4.65, a current ratio of 4.84 and a debt-to-equity ratio of -0.71. Alimera Sciences has a 52 week low of $1.11 and a 52 week high of $1.72. The firm has a market capitalization of $80.21, a P/E ratio of -3.94 and a beta of 2.16.

Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.01. equities research analysts expect that Alimera Sciences will post -0.27 EPS for the current year.

In other news, CEO C. Daniel Myers sold 52,900 shares of the company’s stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $1.23, for a total transaction of $65,067.00. Following the completion of the sale, the chief executive officer now owns 154,411 shares in the company, valued at $189,925.53. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Philip Ashman sold 25,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $1.23, for a total value of $31,365.00. Following the sale, the senior vice president now owns 38,250 shares of the company’s stock, valued at approximately $47,047.50. The disclosure for this sale can be found here. Insiders have sold 184,704 shares of company stock valued at $224,432 in the last 90 days. Company insiders own 14.70% of the company’s stock.

An institutional investor recently raised its position in Alimera Sciences stock. PNC Financial Services Group Inc. lifted its stake in shares of Alimera Sciences, Inc. (NASDAQ:ALIM) by 24.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 180,300 shares of the biopharmaceutical company’s stock after purchasing an additional 35,200 shares during the quarter. PNC Financial Services Group Inc. owned about 0.28% of Alimera Sciences worth $251,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 41.77% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally published by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at

Alimera Sciences Company Profile

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with's FREE daily email newsletter.